

Connect Cambodian Customer to Award-Winning Multi-Cancer Screening in Singapore

*Access to Guardant Health's Multi-Cancer Detection (MCD)
test* as part of Manulife's longevity focus*



Why?

- Cancer is often detected at later stages in Cambodia, when treatment options are more limited and costly.
- Every day, around **50 Cambodians** hear the life-changing words: “YOU HAVE CANCER”, and roughly **38 people** lose their lives **to cancer**.
- Financial uncertainty should never be the reason to delay treatment.

Therefore, the MCD Test* by Guardant Health truly matters.

The Multi-Cancer Detection (MCD) test offers a proactive approach, enabling earlier detection across 10 types of cancer through a simple blood draw.

This solution can significantly improve the chances of timely intervention and better health outcomes, while reducing financial burden and giving families greater confidence to plan ahead.

Manulife is committed to helping people **live longer, healthier lives** - empowering customers to take control of their health before symptoms appear.




Reference:

[\[1\] Health Ministry Sounds Alarm Over Soaring Cancer Burden, Vows Higher-Quality Care](#)

Exclusive Partnership between Manulife & Guardant Health

The partnership with Guardant Health, a global leader in blood-based cancer testing with over a decade of experience¹, is part of Manulife's focus on longevity.

This exclusive partnership introduces the Guardant Health MCD test* to Asia for the first time - empowering customers with earlier cancer detection capabilities.



Multi-Cancer Detection (MCD)* test by Guardant Health

- A test intended to detect 10 cancers with a single blood draw
- Test technology backed by over 1 million oncology blood samples tested¹
- A version of this MCD test has received US FDA Breakthrough Device designation²

 Bladder	 Breast	 Colorectal	 Esophageal	 Stomach (Gastric)
 Liver (Hepatocellular)	 Lung	 Ovarian	 Pancreatic	 Prostate

The Guardant Health MCD Test* is intended to detect **10 cancers** – bladder, breast, colorectal, esophageal, stomach, liver, lung, ovarian, pancreatic and prostate cancer through a single blood draw.

The MCD Test* by Guardant Health is:

- **Scientifically proven**, with technology backed by over 1 million oncology blood samples tested¹
- **Innovative** - Guardant Health's MCD test has received U.S. FDA Breakthrough Device designation²

Source:

1. The US FDA Breakthrough Device designation referenced includes eight cancer types—bladder, colorectal, esophageal, gastric, liver, lung, ovarian, and pancreatic cancer. Source: Guardant Health. FDA Grants Breakthrough Device Designation to Guardant Health's Multi-Cancer Detection (MCD) Test. Published June 3, 2025. <https://investors.guardanthhealth.com/press-releases/press-releases/2025/FDA-Grants-Breakthrough-Device-Designation-to-Guardant-Healths-Shield-Multi-Cancer-Detection-MCD-Test/default.aspx>

2. Data on file. Guardant Health, Inc. Sep, 2025.

SPECIAL OFFER FOR YOU!

Here's how you can access the **Multi-Cancer Detection (MCD)* test**:

1. Speak with a Manulife Insurance Advisor on your financial needs:
<https://bit.ly/4vkNLjc>
2. Purchase a suitable plan
3. Eligible customers will receive a **lucky draw ticket** for a chance to win a complimentary Multi-Cancer Detection (MCD) test worth up to USD 1,500.

Find out more: <https://bit.ly/4vkNLjc>

